You just read:

Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™ and Study Meets Primary Objective

News provided by

Kiadis Pharma

11 Sep, 2013, 07:00 BST